摘要
目的探讨重组人脑利钠肽(rh BNP)对急性心肌梗死经皮冠状动脉介入术(PCI)后并发急性左心衰竭的疗效。方法选择医院2014年1月至2017年1月收治的急性心肌梗死PCI后并发急性左心衰竭患者84例,按照治疗方法不同分为对照组和观察组,各42例。所有患者均行常规治疗方法,对照组予硝酸甘油,观察组予rh BNP。结果术后,观察组患者肌酸激酶(CK)峰值、肌酸激酶同工酶(CK-MB)峰值与肌钙蛋白Ⅰ(cTnⅠ)水平均低于对照组患者(t=2.530,3.187,6.616,P<0.05);观察组临床疗效优于对照组(Z=4.385,P<0.05);完成手术后6个月,观察组患者心肌梗死面积低于对照组患者(t=3.190,P<0.05);两组患者不良反应发生率无明显差异(P>0.05)。结论 rh BNP干预急性心肌梗死PCI后并发急性左心衰竭,可提升疗效,缩小心肌梗死面积。
Objective To investigate the eft）ct of recombinant human brain natriuretic peptide（rhBNP） in the treatment of patientswith acute left heart failure complicated by acute myocardial infarction（AMI） after undergoing percutaneous coronary intervention（PCI）. Methods Totally 84 patients with acute left heart failure complicated by AMI after undergoing PCI admitted to our hospital fi＇om January 2014 to January 2017 were selected and divided into the control group and the ohservation group according to the different treatment methods, 42 cases in each group. All patients were given conventional treatment, on this basis, the control group was given nitroglycerin, while the observation group was given rhBNP. Results After operation, the peak value of creatine kinase（CK）, creatine kinase isoenzyme（CK-MB） and cardiac troponin I（cTn I） in the observation group were significantly lower than those in the control group（t=2.530, 3. 187, 6.616, P 〈 0.05）.The clinical efficacy of the observation group was better than that of the control group （Z = 4. 385, P 〈 0. 05）. 6 months after operation, the infarct size of the patients in the observation group was smaller than that of the control group（t =3. 190, P 〈 0.05）.There was no significant difference in the incidence of adverse reactions between the two groups （P 〉 0. 05）. Conelusion rhBNP in the intervention of patients with acute left heart failure complicated by AMI after undergoing PCI can improve the clinical efficacy and reduce the infarct size.
作者
才振国
车琳琳
王志远
Cai Zhenguol;Che Linlin;Wang Zhiyuan(The Fourth Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,China 150001;Higher Education and Evaluation Center,Heilongfiang University of Chinese Medicine,Harbin,Heilongjiang,China 150001)
出处
《中国药业》
CAS
2018年第17期80-83,共4页
China Pharmaceuticals
关键词
重组人脑利钠肽
心肌梗死
急性左心衰竭
recombinant human brain natriuretic peptide
myocardial infarction
acute left heart failure
